Zoetis Inc. (ZTS)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zoetis Inc. (“Zoetis” or “the Company”) (NYSE: ZTS). Investors who purchased Zoetis securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Zoetis has violated federal securities laws.
Investigation Details:
On April 12, 2024, The Wall Street Journal published an article entitled “What Killed Their Pets? Owners Blame Meds, but Vets Aren’t Sure.” The article reported that “[h]ealth regulators in the U.S. and Europe . . . are conducting reviews” of the Zoetis-produced drugs Librela and Solensia, respectively used to treat arthritis in dogs and cats, after “receiv[ing] thousands of reports of side effects” from pet owners.
On this news, Zoetis’s stock price fell $12.75 per share, or 7.83%, to close at $149.98 per share on April 12, 2024.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Zoetis securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman:
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller,